CA3189680A1 - Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof - Google Patents
Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereofInfo
- Publication number
- CA3189680A1 CA3189680A1 CA3189680A CA3189680A CA3189680A1 CA 3189680 A1 CA3189680 A1 CA 3189680A1 CA 3189680 A CA3189680 A CA 3189680A CA 3189680 A CA3189680 A CA 3189680A CA 3189680 A1 CA3189680 A1 CA 3189680A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugate
- mice
- radionuclide
- chelator
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306109.8 | 2020-09-28 | ||
| EP20306109.8A EP3973999A1 (en) | 2020-09-28 | 2020-09-28 | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
| PCT/EP2021/076107 WO2022063850A1 (en) | 2020-09-28 | 2021-09-22 | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3189680A1 true CA3189680A1 (en) | 2022-03-31 |
Family
ID=74180915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3189680A Pending CA3189680A1 (en) | 2020-09-28 | 2021-09-22 | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230372552A1 (enExample) |
| EP (2) | EP3973999A1 (enExample) |
| JP (1) | JP7824281B2 (enExample) |
| KR (1) | KR20230078690A (enExample) |
| CN (1) | CN116322798A (enExample) |
| AU (1) | AU2021348219A1 (enExample) |
| BR (1) | BR112023003690A2 (enExample) |
| CA (1) | CA3189680A1 (enExample) |
| DK (1) | DK4188457T3 (enExample) |
| ES (1) | ES2989009T3 (enExample) |
| FI (1) | FI4188457T3 (enExample) |
| HR (1) | HRP20241285T1 (enExample) |
| HU (1) | HUE068360T2 (enExample) |
| IL (1) | IL300486A (enExample) |
| LT (1) | LT4188457T (enExample) |
| PL (1) | PL4188457T3 (enExample) |
| PT (1) | PT4188457T (enExample) |
| RS (1) | RS65994B1 (enExample) |
| SI (1) | SI4188457T1 (enExample) |
| SM (1) | SMT202400392T1 (enExample) |
| WO (1) | WO2022063850A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025163082A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2026150109A1 (en) | 2025-01-10 | 2026-07-16 | Molecular Partners Ag | Mesothelin-specific binding constructs and their use in radiotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US20150217006A1 (en) * | 2014-02-06 | 2015-08-06 | Immunomedics, Inc. | Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer |
| CA3050094C (en) | 2017-01-12 | 2024-01-02 | Radiomedix Inc. | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
-
2020
- 2020-09-28 EP EP20306109.8A patent/EP3973999A1/en not_active Withdrawn
-
2021
- 2021-09-22 HR HRP20241285TT patent/HRP20241285T1/hr unknown
- 2021-09-22 PT PT217785021T patent/PT4188457T/pt unknown
- 2021-09-22 EP EP21778502.1A patent/EP4188457B1/en active Active
- 2021-09-22 ES ES21778502T patent/ES2989009T3/es active Active
- 2021-09-22 HU HUE21778502A patent/HUE068360T2/hu unknown
- 2021-09-22 KR KR1020237011366A patent/KR20230078690A/ko active Pending
- 2021-09-22 FI FIEP21778502.1T patent/FI4188457T3/fi active
- 2021-09-22 US US18/246,706 patent/US20230372552A1/en active Pending
- 2021-09-22 LT LTEPPCT/EP2021/076107T patent/LT4188457T/lt unknown
- 2021-09-22 BR BR112023003690A patent/BR112023003690A2/pt unknown
- 2021-09-22 RS RS20241053A patent/RS65994B1/sr unknown
- 2021-09-22 AU AU2021348219A patent/AU2021348219A1/en active Pending
- 2021-09-22 CA CA3189680A patent/CA3189680A1/en active Pending
- 2021-09-22 SM SM20240392T patent/SMT202400392T1/it unknown
- 2021-09-22 DK DK21778502.1T patent/DK4188457T3/da active
- 2021-09-22 JP JP2023518426A patent/JP7824281B2/ja active Active
- 2021-09-22 WO PCT/EP2021/076107 patent/WO2022063850A1/en not_active Ceased
- 2021-09-22 SI SI202130186T patent/SI4188457T1/sl unknown
- 2021-09-22 IL IL300486A patent/IL300486A/en unknown
- 2021-09-22 PL PL21778502.1T patent/PL4188457T3/pl unknown
- 2021-09-22 CN CN202180065166.XA patent/CN116322798A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188457B1 (en) | 2024-07-03 |
| CN116322798A (zh) | 2023-06-23 |
| EP3973999A1 (en) | 2022-03-30 |
| EP4188457A1 (en) | 2023-06-07 |
| ES2989009T3 (es) | 2024-11-25 |
| JP7824281B2 (ja) | 2026-03-04 |
| PL4188457T3 (pl) | 2025-01-07 |
| AU2021348219A1 (en) | 2023-03-09 |
| WO2022063850A1 (en) | 2022-03-31 |
| LT4188457T (lt) | 2024-12-27 |
| SI4188457T1 (sl) | 2025-01-31 |
| SMT202400392T1 (it) | 2024-11-15 |
| HUE068360T2 (hu) | 2024-12-28 |
| JP2023542218A (ja) | 2023-10-05 |
| RS65994B1 (sr) | 2024-10-31 |
| BR112023003690A2 (pt) | 2023-04-04 |
| DK4188457T3 (da) | 2024-08-26 |
| IL300486A (en) | 2023-04-01 |
| HRP20241285T1 (hr) | 2025-01-03 |
| US20230372552A1 (en) | 2023-11-23 |
| KR20230078690A (ko) | 2023-06-02 |
| FI4188457T3 (fi) | 2024-09-23 |
| PT4188457T (pt) | 2024-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2693465C9 (ru) | Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания | |
| JP7541532B2 (ja) | 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物 | |
| US5804157A (en) | Peptide compositions and method of radiolabeling | |
| KR20140053819A (ko) | 방사선요법용 177루테튬-표지 봄베신 유사체 | |
| WO2020210909A1 (en) | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer | |
| EP4188457B1 (en) | Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof | |
| KR20250100754A (ko) | Sstr2를 표적으로 하는 화합물 및 이의 제조 방법과 응용 | |
| US20240100202A1 (en) | Psma-targeting conjugate and uses thereof | |
| KR101658201B1 (ko) | 전립선암의 진단 및 치료를 위한 가스트린유리펩티드수용체 작용서열 기반의 신규한 봄베신 유도체 화합물 | |
| KR101658206B1 (ko) | 전립선암의 진단 및 치료를 위한 가스트린유리펩티드수용체 길항서열 기반의 신규한 봄베신 유도체 화합물 | |
| KR101551232B1 (ko) | Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 | |
| RU2821944C2 (ru) | Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания | |
| Floresta et al. | RSC Medicinal Chemistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240910 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240910 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250609 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250917 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250917 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251008 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251204 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251204 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260805 |